Why the study?
Does prostacyclin infusion improve clinical outcomes and suppress platelet function in patients with acute cerebral infarction?
Does prostacyclin infusion improve clinical outcomes and suppress platelet function in patients with acute cerebral infarction?
Prostacyclin infusion safely suppresses platelet function in acute cerebral infarction, with potential clinical benefit in patients without CT evidence of infarction.
Answers are grounded in this paper and cite their sources.
Prostacyclin may transiently normalize platelet activity in acute cerebral infarction; hypothesis-generating case report that leaves open clinical benefit and need for trials.
We gave prostacyclin infusions to seven patients with acute cerebral infarction. Patients without CT evidence of infarction improved, but those who already had hypodensities on CT did not benefit. Increased platelet activity, measured by plasma beta-thromboglobulin, decreased significantly (p less than 0.01) during prostacyclin administration to normal levels, but rose again after the infusion. These results indicate that prostacyclin can be given safely in doses adequate to suppress platelet function. Our findings encouraged us to proceed with a controlled trial of its clinical efficacy.
No takes yet. Share an insight, caveat, or question.
Miller et al. (1984) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: